Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
November 07, 2022 06:30 ET
|
Beam Therapeutics
Patient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1 Strategy Execution IND-enabling Studies Underway for BEAM-301 for Treatment of...
Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting
November 03, 2022 09:01 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Presents First In Vivo Data Demonstrating Potential of Multiplex Base Editing Approach to Target Disease Drivers of Chronic Hepatitis B Infection
September 19, 2022 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new...
Beam Therapeutics to Participate at the Wells Fargo 2022 Healthcare Conference
September 01, 2022 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results
August 09, 2022 06:30 ET
|
Beam Therapeutics
Patient Enrollment into BEACON Phase 1/2 Trial of BEAM-101 On-track for Second Half of 2022 BEAM-201 IND Submitted to FDA; Currently on Clinical Hold BEAM-102 IND Submission and BEAM-301...
Beam Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
August 02, 2022 08:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application
August 01, 2022 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant
June 27, 2022 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics to Participate in the 2022 Jefferies Healthcare Conference
June 03, 2022 06:42 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results
May 09, 2022 06:30 ET
|
Beam Therapeutics
BEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022 Natural History Study Initiated in People with Sickle Trait...